STOCK TITAN
  1. Home
  2. Sec-filings
  3. CPRX
  4. [Form 4] CATALYST PHARMACEUTICALS, INC. Insider Trading Activity

Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Catalyst Pharmaceuticals Chief Medical Officer William T. Andrews reported routine equity compensation activity involving restricted stock units that convert into common stock. On June 3, 2026, 3,052 restricted stock units were exercised into 3,052 shares of common stock at a conversion price of $0.0000 per share.

Of these, 743 shares were withheld by Catalyst Pharmaceuticals to cover applicable tax obligations, described as a tax-withholding disposition. After this withholding, Andrews directly holds 2,309 shares of common stock. Footnotes explain that each restricted stock unit represents a right to receive one common share upon vesting and that the related derivative securities vest in five equal annual tranches on June 2 of each year from 2026 through 2030.

Positive

  • None.

Negative

  • None.
Insider Andrews William T.
Role Chief Medical Officer
Type Security Shares Price Value
Exercise Common Stock, par value $0.001 per share 3,052 $0.00 --
Tax Withholding Common Stock, par value $0.001 per share 743 $0.00 --
Exercise Restricted Stock Units 3,052 $0.00 --
Holdings After Transaction: Common Stock, par value $0.001 per share — 3,052 shares (Direct, null); Restricted Stock Units — 240,195 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock. Derivative securities vest in equal tranches, 1/5th each on June 2, 2026, 2027, 2028, 2029, and 2030. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on June 3, 2026.
RSUs converted 3,052 shares Restricted stock units exercised into common stock on June 3, 2026
Shares withheld for taxes 743 shares Withheld by Catalyst Pharmaceuticals to satisfy tax obligations
Shares held after transaction 2,309 shares Direct common stock holdings of William T. Andrews after transactions
Derivative RSU balance 240,195 units Total restricted stock units following derivative transaction
Vesting schedule 1/5 annually 2026–2030 RSUs vest June 2 of 2026, 2027, 2028, 2029, 2030
Restricted Stock Units financial
"The filing lists "Restricted Stock Units" as a derivative security that converts into common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
"A transaction coded F is described as a tax-withholding disposition to satisfy applicable withholding taxes."
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative security financial
"The M code is defined as the exercise or conversion of a derivative security related to restricted stock units."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"Footnotes state that each restricted stock unit converts into one share of common stock upon vesting."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
tranches financial
"Derivative securities vest in equal tranches, 1/5 each year from June 2, 2026 through 2030."
Tranches are portions or slices of a larger financing deal—such as a loan, bond issue, or equity round—that are released at different times or under different conditions. For investors they matter because each tranche can carry different risk, interest or payout terms and may be paid only if certain targets are met; think of funding as slices of a cake handed out as progress is made.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Andrews William T.
(Last)(First)(Middle)
355 ALHAMBRA CIRCLE
SUITE 801
(Street)
CORAL GABLES FLORIDA 33134
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.001 per share06/03/2026M3,052A(1)3,052D
Common Stock, par value $0.001 per share06/03/2026F743D(2)2,309D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/03/2025M3,052 (3) (4)Common Stock3,052$0240,195D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
2. Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
3. Derivative securities vest in equal tranches, 1/5th each on June 2, 2026, 2027, 2028, 2029, and 2030.
4. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on June 3, 2026.
/s/ William T. Andrews06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Catalyst Pharmaceuticals (CPRX) report for William T. Andrews?

Catalyst Pharmaceuticals reported that Chief Medical Officer William T. Andrews exercised 3,052 restricted stock units into 3,052 common shares. As part of this routine compensation event, some of the resulting shares were withheld by the company to satisfy applicable tax obligations tied to the vesting.

How many Catalyst Pharmaceuticals (CPRX) shares were withheld for taxes in this Form 4?

The filing shows 743 common shares were withheld to satisfy tax liabilities upon vesting of restricted common stock. This tax-withholding disposition is coded as an F transaction and does not represent an open-market sale by William T. Andrews or a discretionary trading decision.

How many Catalyst Pharmaceuticals (CPRX) shares does William T. Andrews hold after these transactions?

Following the reported transactions, William T. Andrews directly holds 2,309 shares of Catalyst Pharmaceuticals common stock. This figure reflects his position after 3,052 shares from restricted stock units were delivered and 743 of those shares were withheld by the company to cover applicable taxes.

What do the restricted stock units in the Catalyst Pharmaceuticals (CPRX) Form 4 represent?

Each restricted stock unit represents a contingent right to receive one share of Catalyst Pharmaceuticals common stock upon vesting. The footnotes explain that shares must be delivered within sixty days of vesting, and that the first tranche of shares under this award was delivered on June 3, 2026.

How do the Catalyst Pharmaceuticals (CPRX) restricted stock units vest for William T. Andrews?

The derivative securities tied to these restricted stock units vest in five equal tranches. According to the filing, 1/5 of the award vests on each of June 2, 2026, 2027, 2028, 2029, and 2030, providing a multi-year schedule for delivery of common shares as those tranches vest.